RAPID

A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
40 patients (estimated)
Collaborators
Moffitt Cancer Center, The University of Kansas Medical Center
Tags
T Cell (Allogeneic), High Risk
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
2144
NCT Identifier
NCT06552416

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.